HeartBeam (NASDAQ: BEAT) reported financial and operational results for the fourth quarter and full year ended Dec. 31, 2025, highlighting progress toward commercialization following U.S. Food and Drug Administration (FDA) 510(k) clearance of its 12-lead electrocardiogram (ECG) synthesis software in December 2025. The company has initiated a limited market launch targeting concierge and preventive cardiology groups and secured its first commercial partnership with ClearCardio, while also enrolling initial patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection.
Additional developments include completion of a prototype extended-wear 12-lead ECG patch, a strategic collaboration with the Icahn School of Medicine at Mount Sinai to advance AI-enabled ECG algorithms, and the appointment of a new chief commercial officer to support growth initiatives. These steps underscore HeartBeam's commitment to transforming cardiac care by providing powerful cardiac insights through its innovative platform technology.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software clearance in December 2025 marks a significant milestone. HeartBeam holds over 20 issued patents related to technology enablement, positioning it as a leader in cable-free ECG solutions. For more details, the full press release is available at https://ibn.fm/3KQqG.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings. Investors should not place undue reliance on these statements. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. The original release can be viewed on www.newmediawire.com.
